-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $25 Price Target

Benzinga·07/03/2025 12:05:08
Listen to the news
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $25 price target.